Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth A Jacobson

Showing results (521-530 of 599) with videos related to

Pageof 60
Sort By:
Experimental Eye Research|November 3, 2009
Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across speciesZhao Wang, Chi Wai Do, Marcel Y Avila, et al.
Medicinal Research Reviews|July 7, 2017
A<sub>3</sub> Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to TherapyKenneth A Jacobson, Stefania Merighi, Katia Varani, et al.
Bioorganic & Medicinal Chemistry Letters|February 8, 2008
Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-N,N-dialkyluronamides as human A3 adenosine receptor antagonistsLak Shin Jeong, Hyuk Woo Lee, Hea Ok Kim, et al.
Bioorganic & Medicinal Chemistry|June 3, 2008
Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonistsHyojin Ko, Rhonda L Carter, Liesbet Cosyn, et al.
European Journal of Medicinal Chemistry|June 25, 2021
Synthesis and evaluation of adenosine derivatives as A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub> adenosine receptor ligands containing boron clusters as phenyl isosteres and selective A<sub>3</sub> agonistsKatarzyna Bednarska-Szczepaniak, Adam Mieczkowski, Aleksandra Kierozalska, et al.
Journal of Medicinal Chemistry|August 12, 2017
Polypharmacology of N<sup>6</sup>-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A<sub>3</sub> Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic PotentialJinha Yu, Seyeon Ahn, Hee Jin Kim, et al.
ACS Chemical Biology|October 10, 2014
Exploring a 2-naphthoic acid template for the structure-based design of P2Y14 receptor antagonist molecular probesEvgeny Kiselev, Matthew O Barrett, Vsevolod Katritch, et al.
British Journal of Pharmacology|October 30, 2020
Update of P2X receptor properties and their pharmacology: IUPHAR Review 30Peter Illes, Christa E Müller, Kenneth A Jacobson, et al.
Trends in Pharmacological Sciences|February 1, 2003
Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor familyMaria P Abbracchio, Jean-Marie Boeynaems, Eric A Barnard, et al.
Journal of Medicinal Chemistry|August 22, 2003
N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptorLak Shin Jeong, Dong Zhe Jin, Hea Ok Kim, et al.
Pageof 60

Showing results (521-530 of 599) with videos related to

Sort By:
Pageof 60
Experimental Eye Research|November 3, 2009
Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across speciesZhao Wang, Chi Wai Do, Marcel Y Avila, et al.
Medicinal Research Reviews|July 7, 2017
A<sub>3</sub> Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to TherapyKenneth A Jacobson, Stefania Merighi, Katia Varani, et al.
Bioorganic & Medicinal Chemistry Letters|February 8, 2008
Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-N,N-dialkyluronamides as human A3 adenosine receptor antagonistsLak Shin Jeong, Hyuk Woo Lee, Hea Ok Kim, et al.
Bioorganic & Medicinal Chemistry|June 3, 2008
Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonistsHyojin Ko, Rhonda L Carter, Liesbet Cosyn, et al.
European Journal of Medicinal Chemistry|June 25, 2021
Synthesis and evaluation of adenosine derivatives as A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub> adenosine receptor ligands containing boron clusters as phenyl isosteres and selective A<sub>3</sub> agonistsKatarzyna Bednarska-Szczepaniak, Adam Mieczkowski, Aleksandra Kierozalska, et al.
Journal of Medicinal Chemistry|August 12, 2017
Polypharmacology of N<sup>6</sup>-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A<sub>3</sub> Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic PotentialJinha Yu, Seyeon Ahn, Hee Jin Kim, et al.
ACS Chemical Biology|October 10, 2014
Exploring a 2-naphthoic acid template for the structure-based design of P2Y14 receptor antagonist molecular probesEvgeny Kiselev, Matthew O Barrett, Vsevolod Katritch, et al.
British Journal of Pharmacology|October 30, 2020
Update of P2X receptor properties and their pharmacology: IUPHAR Review 30Peter Illes, Christa E Müller, Kenneth A Jacobson, et al.
Trends in Pharmacological Sciences|February 1, 2003
Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor familyMaria P Abbracchio, Jean-Marie Boeynaems, Eric A Barnard, et al.
Journal of Medicinal Chemistry|August 22, 2003
N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptorLak Shin Jeong, Dong Zhe Jin, Hea Ok Kim, et al.
Pageof 60